Long-term SPG stimulation therapy for prevention of vascular dementia

• US 7,860,569 B2
• Filed: 10/18/2007
• Issued: 12/28/2010
• Est. Priority Date: 10/18/2007
• Status: Active Grant

• Current Assignee: BrainsGate Ltd.
• Original Assignee: BrainsGate Ltd.
• Inventors: Solberg, Yoram, Altman, Hernan
• Primary Examiner(s): Layno; Carl H
• Assistant Examiner(s): Bays; Pamela M
• Application Number:
  US11/874,529
• Publication Number:
  US 20090105783A1
• Time in Patent Office: 1,167 Days
• Field of Search: 607/1, 607/2, 607/45, 607/46, 607/48, 607/118, 600/26
• US Class Current: 607/45
• CPC Class Codes: A61N 1/0546 Nasal electrodes
• CPC Class Codes: A61N 1/0548 Oral electrodes
• CPC Class Codes: A61N 1/0551 Spinal or peripheral nerve electrodes
• CPC Class Codes: A61N 1/36082 Cognitive or psychiatric applications, e.g. dementia or Alzheimer's disease

Abstract

A method is provided that includes identifying that a subject is at risk of suffering from vascular dementia (VaD). Responsively to the identifying, a risk of development of the VaD is reduced by applying electrical stimulation to a site of the subject selected from the group consisting of: a sphenopalatine ganglion (SPG), a greater palatine nerve, a lesser palatine nerve, a sphenopalatine nerve, a communicating branch between a maxillary nerve and an SPG, an otic ganglion, an afferent fiber going into the otic ganglion, an efferent fiber going out of the otic ganglion, an infraorbital nerve, a vidian nerve, a greater superficial petrosal nerve, and a lesser deep petrosal nerve; and configuring the stimulation to induce at least one neuroprotective occurrence selected from the group consisting of: an increase in cerebral blood flow of the subject, and a release of one or more neuroprotective substances. Other embodiments are also described.

Claims

1. A method comprising:

identifying that a subject is at particular future risk of suffering from vascular dementia (VaD) even though the subject displays no symptoms of VaD at the time of the identifying; and

responding to the identifying by reducing a risk of development of the VaD by;

applying electrical stimulation to a site of the subject at least intermittently during a period having a duration of at least four weeks, the site selected from the group consisting of;

a sphenopalatine ganglion (SPG), a greater palatine nerve, a lesser palatine nerve, a sphenopalatine nerve, a communicating branch between a maxillary nerve and an SPG, an otic ganglion, an afferent fiber going into the otic ganglion, an efferent fiber going out of the otic ganglion, an infraorbital nerve, a vidian nerve, a greater superficial petrosal nerve, and a lesser deep petrosal nerve, and

configuring the stimulation applied to the site to induce at least one neuroprotective occurrence selected from the group consisting of;

an increase in cerebral blood flow (CBF) of the subject, and a release of one or more neuroprotective substances.

2. The method according to claim 1, wherein identifying comprises identifying that the subject suffers from low cerebral blood perfusion.

3. The method according to claim 1, wherein identifying comprises identifying that the subject suffers from reduced cardiac output.

4. The method according to claim 1, wherein applying the stimulation comprises implanting an electrical stimulator in a vicinity of the site, and activating the stimulator to apply the stimulation.

5. The method according to claim 1, wherein the site includes the SPG, and wherein applying the stimulation comprises applying the stimulation to the SPG.

6. The method according to claim 1, wherein identifying comprises identifying that the subject has suffered from a stroke, and is thus at particular future risk of suffering from post-stroke dementia.

7. The method according to claim 6, wherein identifying comprises assessing an age of the subject at a time of the stroke.

8. The method according to claim 6, wherein identifying comprises assessing a severity of the stroke.

9. The method according to claim 6, wherein identifying comprises identifying that the subject suffers from hypertension.

10. The method according to claim 6, wherein identifying comprises assessing an indication of cognitive function of the subject during an acute stage of the stroke.

11. The method according to claim 1, wherein configuring the stimulation comprises setting a strength of the stimulation to be insufficient to induce a significant increase in permeability of a blood-brain barrier (BBB) of the subject.

12. The method according to claim 1, wherein the at least one neuroprotective occurrence includes the increase in the CBF, and wherein configuring comprises configuring the stimulation to induce the increase in the CBF.

13. The method according to claim 1, wherein applying the electrical stimulation comprises applying excitatory electrical stimulation to the site.